Navigation Links
NIH funds investigation of inhaled lung cancer treatment
Date:4/12/2011

April 11, 2011 (BRONX, NY) Just as inhaling cigarette smoke can cause lung cancer, inhaling medication may treat it. Two researchers at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $2.4 million grant from the National Institutes of Health to clinically develop an inhaled therapy for lung cancer to be used before the cancer becomes malignant and spreads.

The grant recipients are Roman Perez-Soler, M.D., professor of medicine and associate director of clinical research at Albert Einstein Cancer Center; and Yiyu Zou, Ph.D., associate professor of medicine. Dr. Perez-Soler is also chair of oncology at Montefiore Medical Center.

Lung cancer is the leading cause of cancer mortality among men and women in the U.S. Each year, more than 220,000 are diagnosed and about 150,000 people die from the disease. The average five-year survival rate is only 15 percent, largely because nearly 80 percent of cases are diagnosed after the cancer has spread from the lungs to other organs in the body. Drs. Perez-Soler and Zou will take advantage of the fact that, for many years, the disease is confined to the bronchial epithelium (surface cells of the airways), where it lingers and develops in a premalignant state.

The research project involves inhaling a drug called 5-azacytidine to target the bronchial epithelium. 5-azacytidine is a demethylating agent, meaning it strips off methyl groups that have bound to genes and rendered them inactive. Since removing methyl groups can reactivate genes that suppress tumors, drugs such as 5-azacytidine can potentially treat a number of different types of cancers.

The first two years of the federally-funded study will focus on a mouse model of premalignant lung cancer, to determine what dose is likely to be safe and effective in humans. In years three through five, researchers will conduct a Phase I "feasibility and proof of principle" study in which patients with advanced non-small cell lung cancer (the most common type), and who no longer respond to standard therapy, will inhale 5-azacytidine. Albert Einstein College of Medicine has filed a patent application related to this research, which is available for licensing to partners interested in further testing and developing this treatment.

The ultimate aim of the research is to intervene with inhaled 5-azacytidine at an earlier, precancerous stage, when vital genes have been silenced but cancer has not yet developed. Using the therapy in this way it might prevent lung cancer from developing in people with a history of cigarette smoking. According to the Centers for Disease Control and Prevention, there are about 46 million adult smokers in the U.S.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Cystic Fibrosis Foundation funds Marshall research
2. NSF funds study of landscape restoration effects on Pennsylvania stream
3. Keck Foundation funds work on tiny, implantable computers to restore lost brain functions
4. FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
5. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
6. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
7. NIH funds center at Arizona State to battle infectious diseases
8. French national research agency funds PREDIMOL project
9. NHGRI funds development of third generation DNA sequencing technologies
10. $22.5 million grant funds international study of membrane proteins
11. NSF funds innovative approach to biomimetic nanofiber bone regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family ... and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... and administered by the New York Academy of Sciences to honor the excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
Breaking Biology Technology: